Facilitated self‑selection: convenience at the counter, risk at the point of decision?
The Royal Pharmaceutical Society (RPS) has issued a position statement and guidance supporting facilitated self‑selection, where a community pharmacy chooses to implement such models, provided safeguards and supervision are demonstrably in place. The General Pharmaceutical Council (GPhC) defines this as people picking up P‑medicines themselves before a sale is completed under pharmacist supervision.
The PDA’s view is clear and opposes facilitated self‑selection. The PDA’s report, ‘Beyond Convenience’ and subsequent statements highlight the absence of an adequate evidence base. The dilution of pharmacist intervention at the time when patients make choices, and the real‑world risks this creates (especially given health‑literacy challenges and polypharmacy) is real. In the PDA’s 2024-member survey (n=1,323), 93% of respondents opposed self‑selection, with the majority citing supervision difficulties and risks of confrontation when challenging inappropriate choices.
Professional consistency also matters. Until recently, RPS materials stressed that P‑medicines should not be accessible by self‑selection. The RPS now supports facilitated models, with ‘robust processes’, despite acknowledging ongoing evidence gaps and no peer-reviewed evidence published. That shift, coupled with the regulator’s evolving language, has created ambiguity for front‑line teams about what safe supervision looks like.
In real terms, once a choice of product is already in a patient’s hand, so-called facilitated self-selection can only facilitate the sales transaction. A professional or clinical judgement that the medicine is, in fact, inappropriate requires the pharmacist to override the patient’s selection and risks a dispute.
The bigger picture: pharmacy should be the NHS’s front door, not the shop floor
For decades, community pharmacy has argued, and policymakers increasingly agree, that pharmacies should function as a front door to the NHS and an integral backbone of primary care, delivering accessible clinical services such as Pharmacy First. NHS England and NHS Confederation have explicitly framed pharmacy’s role in this way, while the all-party parliamentary group (APPG) on pharmacy calls for a nationally consistent, walk‑in front‑door service. This strategic trajectory is clinical and system‑facing, not retail‑led. Facilitated self‑selection risks pulling the sector back towards a shop model rather than a professional healthcare location.
Handing out ‘checked and bagged’ prescriptions in the pharmacist’s absence: targeted flexibility with clearer guardrails
By contrast, the Human Medicines (Authorisation by Pharmacists and Supervision by Pharmacy Technicians) Order 2025 enables, from 7 January 2026, authorisation for competent team members to hand out prescriptions that have been clinically checked and dispensed with no further pharmacist intervention required. The remaining provisions (e.g., broader technician authorisations) are scheduled for 10 December 2026 following standards and guidance. Crucially, this is enabling, not mandatory and pharmacists retain discretion.
The RPS has published guidance to help teams operationalise this safely. While it is helpful, its framing reads largely as an implementation toolkit for owners and organisations, emphasising ‘what’s changed’ standard Operating Procedures (SOP) updates, checklists and roles & responsibilities, rather than a clinician‑centred guide that supports a Responsible Pharmacist (RP), including locum pharmacists, in navigating the complexities and accountability risks that arise in live practice. The page prioritises operational artefacts (e.g., SOP prompts, escalation lists, and a checklist of considerations) and signposts some material behind member login (e.g., RP rules and professional judgement), which may limit practical, day‑to‑day utility across the workforce. What’s missing is explicit support on decision‑rights, withdrawal of authorisations, conflict management when authorisation is contested, and protections for individual pharmacists facing ambiguous scenarios, exactly where risk transfers can occur in the hand‑out step. In short, while it may help pharmacy businesses to implement a process and does less to equip pharmacists to own the clinical and legal consequences of that process.
Comparing the trajectories
Both developments claim to release pharmacist capacity. Yet they differ fundamentally in where risk is managed. Facilitated self‑selection moves the pharmacist’s intervention after a patient has psychologically ‘chosen’, raising risks of misuse, delayed diagnosis, and conflict. These concerns are echoed by PDA members and the published evidence review landscape.
The ‘checked and bagged’ change, however, preserves the pharmacist’s clinical check and restricts delegation to the final hand‑out step, with explicit timelines, regulatory frameworks, and guidance. As government and regulator materials emphasise, this is about using skill‑mix without introducing remote supervision or removing the pharmacist’s responsibility for clinical decisions. On balance, this pathway aligns more closely with a clinical, patient‑facing pharmacist and a safer redistribution of tasks.
Implications for daily practice: questions that should be asked
- Are SOPs explicit about which prescriptions can be handed out in the pharmacist’s absence, including the escalation triggers (e.g., high‑risk medicines, safeguarding cues, counselling needs)?
- How will authorisations be recorded and withdrawn to protect accountability (including employed, locum pharmacists and part‑day cover)?
- What training and signage would be required if an owner proposed facilitated self‑selection, and is there a defensible evidence base that risk is acceptably mitigated? Or, in cases where the RP decided that there are not defensible evidence base mitigated strategies in place?
- Are pharmacists able to say ‘no’ in practice? Both frameworks are optional and pharmacists should feel professionally supported to decline models that compromise patient safety or professional standards. However, in the real world what protections exist for employed or locum pharmacists who as RPs disagree with a pharmacy owner’s view.
PDA’s position
The PDA supports modernisation that strengthens clinical pharmacy, not keeping it established in retail transactions.
The PDA therefore opposes facilitated self‑selection of P‑medicines and calls for transparent, evidence‑led policy that protects the public and the profession.
The PDA supports cautious, governed implementation of the ‘checked and bagged’ provision, with rigorous SOPs, training, and accountability so that released time genuinely translates into more pharmacist‑delivered clinical care and professional development.
The PDA wants a system that enables professionals to say ‘no’ without fear of detriment.
Learn more
- Facilitated self-selection of pharmacy medicines RPS Position Statement
- Facilitated self-selection of pharmacy (P) medicines RPS Pharmacy Guide
- GPhC FAQ: self-selection and open display of Pharmacy medicines
- Beyond Convenience
- PDA’s response to the RPS Position on facilitated self-selection of P medicines
- More than 90% of pharmacists oppose self-selection of P medicines, says PDA
- Consultation outcome Pharmacy supervision consultation: government response
- Draft legislation sets out future of pharmacy supervision
- The Human Medicines (Authorisation by Pharmacists and Supervision by Pharmacy Technicians) Order 2025
- GPhC welcomes new legislation and gets ready to consult on supporting standards and rules
- Authorisation by a pharmacist who is absent or treated as absent – handing out checked and bagged prescriptions RPS Pharmacy Guide
- From 7 January 2026 the law changes regarding pre-checked and bagged prescriptions
- Over 10,000 NHS pharmacies begin treating people for common conditions
- Pharmacy stands ready to provide a reimagined front door to the NHS
- APPG calls for Pharmacy First to be national walk-in service
- A vision for community pharmacy
Not yet a PDA member?
If you have not yet joined the PDA, we encourage you to join today and ask your colleagues to do the same.
Membership is FREE to pharmacy students, trainee pharmacists and for the first three months of being newly qualified.
Read about our key member benefits here.